Applications published 28 November 2007

Ophthalmological compsn and use mode thereof
Laboratoires THEA 1858481*

Methods of reducing microbial contamination
3M Innovative Properties 1858482*

• Delivery system for multiple drugs
Dr Reddy's Laboratories Ltd; Dr Reddy's Laboratories Inc 1858483*

• Microemulsions of cannabinoid receptor binding compounds
Novartis 1858484*

• Medicament delivery formulations, devices and methods
Honeywell International 1858485*

• Methods and compsns for minimising accrual of inhalable insulin in the lungs
Mannkind 1858486*

• Chemically defined stabiliser compsn
Intervet International 1858487*

• Tigecycline compsns and methods of preparation
Wyeth 1858488*

• Methods and compsns for modified release of nutritional supplements
Mannatech 1858489*

• Pharmaceutical forms with improved pharmacokinetic properties
Bayer Healthcare 1858490*

• Sublingual coated tablet
Ethypharm 1858491*

• Oral osmotic dosage form having a high flux element
Alza 1858492*

• Oral drug delivery system
Sun Pharmaceutical Industries 1858493*

• New soft gelatin capsules
Altergon 1858494*

• Device for delivery of TRPV1 agonists
Neurogesx 1858495*

• Transdermal therapeutic system for the administration of analgesics
Grunenthal 1858496*

• Use of compounds that interfere with the hedgehog signalling pathway for the manufacture of a medicament for preventing, inhibiting and/or reversing ocular diseases related with ocular neovascularisation
Fondazione Telethon 1858497*

• Use of microtubule stabilising compounds for the treatment of lesions of CNS axons
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften 1858498*

• Methods for the treatment of retinal degenerative disease
University of Washington 1858499*

• Medicinal compsns of salts, chelates and/or free acids of alpha hydroxyl organic acids and related processes and methods
Pero, Ronald 1858500*

• NMDA receptor antagonists in the medical intervention of metabolic disorders
Hermanussen, Michael 1858501*

• Methods and pharnaceutical compsns for the treatment of neurological damage
Acure Pharma 1858502*

• Topical gels compsns
ISW Group 1858503*

• Carnitine-containing peritoneal dialysis solution having improved biocompatibility
Sigma-Tau Industrie Farmaceutiche Riunite 1858504*

• Polyacetylen compounds isolated from Cussonia
University of Basel; University of Bern; Swiss Tropical Institute 1858505*

• Methods of treating ear infections
3M Innovative Properties 1858506*

• Polyphenol coxib combinations and methods
Mitsui Norin 1858507*

• Compounds having anticancer properties
Vital Health Sciences 1858508*

• Novel cathepsin C inhibitors and their use
Glaxo Group 1858509*

• Antifungal compsns comprising setaconazol and hydrocortisone and/or an antibacterial quinolone compound
Ferrer Internacional 1858510*

• Pharmaceutical compsns comprising sirolimus and/or an analogue thereof
LifeCycle Pharma 1858511*

• Methods of treating cancer using PPAR-gamma antagonists
Immunomedics; Centre for Molecular Medicine and Immunology 1858512*

• Diphenyl substituted cycloalkanes, compsns containing such compounds and methods of use
Merck; Merck Frosst Canada 1858513*

• Pharmaceutical tablets of crystalline type II artisanale
syntonic 1858514*

• Pharmaceutical compsns for the treatment and/or prevention of anxiety disorders
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 1858515*

• Pharmaceutical compsns for the treatment and/or prevention of depression
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 1858516*

• Pharmaceutical compsns for the treatment and/or prevention of schizophrenia and related diseases
Boehringer Ingelheim International; Boehringer Ingelheim Pharma 1858517*

• A combination treatment for enhancing diuresis
Orion 1858518*

• Orally used compatible solute containing agents
bigots Aldridge-Brownhills furl biotechnologist optimiser 1858519*

• Quinazolineone T-cell calcium channel antagonists
Merck 1858520*

• Compounds and compsns as protein kinase inhibitors
IRM 1858521*

• Pharmaceutically acceptable carrier for ophthalmic compsns
Nascent Pharmaceutical; De C Du Mee, Charles; Barnett, Gene; Coy, Michael 1858522*

• Combination therapy for topical application in the treatment of dry eye syndrome
Nascent Pharmaceutical 1858523*

• Compsns and methods for treatment of autoimmune and related diseases
The Scripps Research Institute 1858524*

• Organic nitric oxide donor salts of antimicrobial compounds, compsns and methods of use
Nitromed 1858525*

• Glucoalkaloid and TLR agonist combinations and various uses thereof
Solbec Pharmaceuticals 1858526*

• Oral dosage forms of gemcitabine derivatives
Clavis Pharma 1858527*

• Process for crystallising lactose particles for use in pharmaceutical formulations
Glaxo Group 1858528*

• Blood soluble drag reducing hyaluronic acid
Lifecore Biomedical; University of Pittsburgh 1858529*

• Immunostimulating polyphosphazene compounds
Parallel Solutions 1858530*

• Use of copper silicate for the control of herpes infections
Conve 1858531*

• Compsns and methods for less immunogenic protein formulations
The Research Foundation of State University of New York 1858532*

• Use of amniotic fluid (AF) in treating ocular disease and injury
The Johns Hopkins University School of Medicine 1858533*

• Bacteriocins and novel bacterial strains
The United States of America, as represented by the Secretary of Agriculture; State Research Centre for Applied Microbiology, Russia 1858534*

• Compsns comprising actinidia and methods of use thereof
Efficas; Pangenomics; Jeon, Hyang 1858535*

• Medicaments consisting of plant extracts as a lipase inhibitor
Schrezenmeir, Juergen 1858536*

• Prion-specific peptide reagents
Novartis Vaccines and Diagnostics 1858537*

• Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
Biomarck Pharmaceuticals 1858538*

• Methods, compsns and articles of manufacture for contributing to the treatment of solid tumours
Spectrum Pharmaceuticals; The Board of Trustees of the University of Illinois 1858539*

• Stabilised compsns containing natriuretic peptides
Bio-Rad Laboratories 1858540*

• Use of modulators of compounds of TGF-Beta superfamily to regulate hepcidin-mediated iron metabolism
The General Hospital Corp 1858541*

• Compsns and methods for treating vascular permeability
Joslin Diabetes Centre 1858542*

• Glycopegylated granulocyte colony stimulating factor
Neorse Technologies 1858543*

• IL-10 related peptides for wound healing
Renovo 1858544*

• Methods and pharmaceutical positions for treating type 1 diabetes mellitus and other conditions
Curedm 1858545*

• Modified transferring fusion proteins
Biorexis Pharmaceutical 1858546*

• Immunogenic compsns
Nanocore Biotecnologia 1858547*

• Compsns of HSP60 peptides and viral antigens for vaccination and diagnosis
Yeda Research & Development; BG Negev Technologies and Applications 1858548*

• Compsn comprising the N-terminal region of leishmania-histone H2B, use therefor for inducing an immune response
Institut Pasteur; Institut Pasteur de Tunis 1858549*

• Vaccine formulation
The Secretary of State for Defence 1858550*

• Combination vaccines with whole cell pertussis antigen
Novartis Vaccines and Diagnostics 1858551*

• Compsn comprising human IGG2 antibody and a chelating agent
Pharmacia & Upjohn 1858552*

• Methods for decreasing calcification
Amgen 1858553*

• New pharmaceutical compsns based on anticholinergics and PDE 5-inhibitors
Boehringer Ingelheim International 1858554*

• Fucoidan compsns and methods of dietary and nutritional supplements
Supranaturals 1858555*

• Vehicle for topical delivery of anti-inflammatory agents
Alpharx 1858556*

• Methods and compsns for modulating body weight and for treating weight disorders and related diseases
Yeda Research and Development 1858557*

• NOD1 as an anti-tumour agent
The Scripps Research Institute 1858558*